Superbugs: How they evolve and minimize the cost of resistance
- 1 October 1999
- journal article
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 1 (5) , 464-469
- https://doi.org/10.1007/s11908-999-0060-0
Abstract
The increasing frequency with which antimicrobial-resistant microorganisms have emerged in hospitals and communities has alarmed public health officials worldwide. The emergence of resistance results from the evolution of the sometimes elegant resistance mechanisms that create so-called superbugs, which disseminate by clonal spread or exchange resistance traits with other microorganisms. One major contributor to the emergence of resistance is selection intensity, which is determined by the volume of drug consumption by humans and the agriculture industry. De novo or acquired resistance is often initially associated with a cost to fitness of the microorganism. It therefore seems reasonable to assume that reducing the volume of drug use would slow the evolution and reduce the prevalence of resistance. This assumption has led to worldwide attempts to control the inappropriate use of antimicrobials in the hope of controlling the pandemic of antibiotic resistance. However, microorganisms have learned to adapt in order to survive in ever-changing environments. Superbugs have evolved numerous mechanisms that reduce or eliminate the cost of resistance, and such adaptations may minimize the potential benefits of programs aimed at reducing the volume of drug use. It therefore behooves us to look to other disciplines—such as population genetics, ecology, and mathematical biology—to help us tackle this perplexing and important problem.Keywords
This publication has 46 references indexed in Scilit:
- The Cost of Antibiotic Resistance—from the Perspective of a BacteriumPublished by Wiley ,2007
- Mobile Gene Cassettes and Integrons: Moving Antibiotic Resistance Genes in Gram-Negative BacteriaPublished by Wiley ,2007
- Resistance to Antimicrobial Chemotherapy: A Prescription for Research and ActionThe Lancet Healthy Longevity, 1998
- Serotype 19A Variants of the Spanish Serotype 23F Multiresistant Clone ofStreptococcus pneumoniaeMicrobial Drug Resistance, 1998
- To be a mutator, or how pathogenic and commensal bacteria can evolve rapidlyTrends in Microbiology, 1997
- Non‐palindromic attI sites of integrons are capable of site‐specific recombination with one another and with secondary targetsMolecular Microbiology, 1997
- The biological cost of antimicrobial resistanceTrends in Microbiology, 1997
- The Garrod Lecture Evasion of antibiotic action by bacteriaJournal of Antimicrobial Chemotherapy, 1996
- Prophylaxis with Amoxicillin or Sulfisoxazole for Otitis Media: Effect on the Recovery of Penicillin-Resistant Bacteria from ChildrenClinical Infectious Diseases, 1996
- Inducible Type I βlactamases of Gram-negative bacteria and resistance to βlactam antibioticsJournal of Antimicrobial Chemotherapy, 1986